Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.64 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.64 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30484271 | 1.00 | CYP4F2 (0.64) | CYP4F2CYP4A11MMP1CYP3A4TAAR1 | |
| SCHEMBL1239104 | 0.85 | TAAR1 (0.51) | CYP4F2CYP4A11CYP3A4TAAR1TSHR | |
| SCHEMBL2382627 | 0.84 | HTT (0.50) | CYP4F2CYP4A11MAPK1NPC1POLB | |
| SCHEMBL2890956 | 0.82 | CYP4F2 (0.57) | CYP4F2CYP4A11NPC1POLBRAB9A | |
| SCHEMBL4159177 | 0.82 | TNKS2 (0.56) | TAAR1TSHRMAPK1POLBLMNA | |
| SCHEMBL2432106 | 0.82 | PTGS2 (0.52) | CYP4F2CYP4A11TAAR1TSHRMAPK1 | |
| SCHEMBL29997296 | 0.81 | CA2 (0.68) | CYP3A4NPC1POLBRAB9ACA2 | |
| SCHEMBL28170408 | 0.81 | CA2 (0.68) | CYP3A4NPC1POLBRAB9ACA2 | |
| SCHEMBL119395 | 0.81 | CA2 (0.68) | CYP3A4NPC1POLBRAB9ACA2 | |
| SCHEMBL31163873 | 0.81 | CYP4F2 (0.60) | CYP4F2CYP4A11TSHRPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3664213-B1 | ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME | LG ENERGY SOLUTION LTD (KR) | 2023-09-13 | — | — | EP | claimed |
| EP-3547414-B1 | LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG ENERGY SOLUTION LTD (KR) | 2023-09-13 | — | — | EP | claimed |
| US-11495824-B2 | Electrolyte for lithium metal battery and lithium metal battery comprising same | LG ENERGY SOLUTION, LTD. (KR) | 2022-11-08 | — | — | US | claimed |
| CN-110192294-B | Lithium electrode and lithium secondary battery comprising same | 株式会社LG新能源 | 2022-09-20 | — | — | CN | claimed |
| CN-111033864-B | Electrolyte for lithium metal battery and lithium metal battery comprising same | 株式会社LG新能源 | 2022-08-12 | — | — | CN | claimed |
| US-20200203759-A1 | ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-06-25 | — | — | US | claimed |
| EP-3664213-A2 | ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME | LG Chem, Ltd. (KR) | 2020-06-10 | — | — | EP | claimed |
| US-20190319272-A1 | LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG CHEM, LTD. (KR) | 2019-10-17 | — | — | US | claimed |
| EP-3547414-A2 | LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG Chem, Ltd. (KR) | 2019-10-02 | — | — | EP | claimed |
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| EP-3664213-B1 | ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME | LG ENERGY SOLUTION LTD (KR) | 2023-09-13 | — | — | EP | disclosed |
| EP-3547414-B1 | LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG ENERGY SOLUTION LTD (KR) | 2023-09-13 | — | — | EP | disclosed |
| US-11495824-B2 | Electrolyte for lithium metal battery and lithium metal battery comprising same | LG ENERGY SOLUTION, LTD. (KR) | 2022-11-08 | — | — | US | disclosed |
| CN-110192294-B | Lithium electrode and lithium secondary battery comprising same | 株式会社LG新能源 | 2022-09-20 | — | — | CN | disclosed |
| CN-1479727-A | Piperazinylpyrazine compounds as agonists or antagonists of the 5-hydroxytryptamine 5 HT-2 receptor | �Ȱ�ά����ķ�ɷݹ�˾ | 2004-03-03 | — | — | CN | disclosed |
| WO-2003051370-A1 | SELECTIVE DOPAMINE D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| EP-1140924-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| WO-2000035915-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | CYP4F2 3925/4885CYP4A11 4174/4885MMP1 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.